{"groups":[{"description":"Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.","id":"FG000","title":"Treatment (Trametinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Physician Determines It Is In Patient's Best Interest"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Progressive Disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}